NSC, Sanofi, and A*STAR Partner to Advance Acne Treatment Research
NSC, Sanofi, and A*STAR Partner to Advance Acne Treatment Research
In addition, a translational study will be conducted to explore key biological markers that impact acne severity.The collaboration includes a phase 1 clinical study to start in the second quarter of 2025.
該合作包括在2025年第二季度開始的一項第1階段臨床研究。
The National Skin Centre Singapore, Sanofi, and the Agency for Science, Technology, and Research (A*STAR) have signed a memorandum of understanding (MoU) to advance research in acne treatment.
新加坡國家皮膚中心、賽諾菲安萬特和科學技術研究局（A*STAR）已簽署諒解備忘錄，以推動痤瘡治療研究。
The collaboration includes a phase 1 clinical study involving patients with mild acne, expected to commence in the second quarter of 2025.
合作包括涉及輕度痤瘡患者的第1期臨床研究，預計將於2025年第二季度開始。
In addition, a translational study will be conducted to explore key biological markers that impact acne severity.
此外，將開展一項轉化研究，以探索影響痤瘡嚴重程度的關鍵生物標誌物。
The chronic inflammatory skin condition affects a significant portion of the population, with approximately 80% of teenagers and an increasing number of adults—an estimated 40%—experiencing the condition.
這種慢性炎症性皮膚狀況影響着大部分人口，大約80%的青少年和數量不斷增加的成年人（估計約40%）患有這種狀況。
譯文內容由第三人軟體翻譯。
